If the back of the eye tends to steal the spotlight (retina, we’re looking at you), the front of the eye is where the plot quietly thickens.
Anterior segment diseases, those affecting the cornea, conjunctiva, and ocular surface, might seem more approachable at first blink, but clinical trials here have a way of turning simple stories into intricate epics. At Ora, we’ve learned that working on the surface doesn’t mean staying superficial – quite the opposite. The front of the eye is full of nuance, mystery, and just enough unpredictability to keep even the most seasoned trial designer on their toes (and occasionally reaching for another cup of coffee). So, let’s pull focus to the front of the eye, where the real magic and mischief often happens.
First up in our tale: finding patients. For rare or niche conditions like Neurotrophic Keratitis (NK) or Fuchs’ endothelial dystrophy, patients don’t simply line up at the door—they’re more like rare birds that require careful spotting, precise identification, and a network of seasoned observers. These diseases can be underdiagnosed or mistaken for something else entirely, which means recruitment becomes part science, part art, and part detective novel. Meanwhile, in more common conditions like dry eye or ocular allergy, the challenge shifts from scarcity to specificity. There are plenty of patients, but finding the right ones, those whose signs and symptoms align just so, can feel like trying to catch a breeze in a bottle. The ocular surface, as it turns out, has a personality all its own.
A patient may feel miserable but look clinically “fine,” or vice versa.
Then we arrive at the curious case of endpoints, those all-important measures that tell us whether a treatment is truly working. In anterior segment trials, signs and symptoms don’t always see eye to eye (yes, we went there). A patient may feel miserable but look clinically “fine,” or vice versa. Regulators, quite reasonably, want endpoints that are meaningful, measurable, and reproducible—but creating them often requires a blend of rigor, creativity, and a willingness to color outside the lines of precedent. It’s a bit like inventing a new language while simultaneously using it in a conversation. Success here depends on close collaboration with regulatory bodies and a shared commitment to defining what “better” really looks like for patients.
Funding adds another twist to the plot. For emerging indications like NK, the challenge is convincing investors to take a chance on smaller, more specialized populations. For established areas like dry eye and allergy, it’s the opposite problem: the field is crowded, and new therapies must not only work, they must shine. Standing out requires clear differentiation, compelling data, and a story that’s as strong scientifically as it is strategically. It’s a high bar, but one that reflects the growing sophistication of ophthalmology as a whole. In this space, incremental isn’t always enough. Innovation needs to be both meaningful and measurable.
And this is where the story takes a hopeful turn. At Ora, we’ve made it our mission to help define that “measurable” piece by developing and validating novel endpoints that capture the full picture of patient experience. These tools don’t just help therapies cross the regulatory finish line. They help them stand out once they get there, demonstrating real clinical impact and competitive value. A shining example comes from the recent FDA approval of treatments for Demodex blepharitis, where Ora-developed scales brought clarity (and a bit of order) to the once-murky task of quantifying collarettes and mite burden. It’s proof that when the right tools meet the right collaboration across companies, clinicians, and regulators, progress accelerates in meaningful ways.
Across the field, we’re seeing more companies embrace this spirit of innovation. Biotech pioneers are exploring new approaches for Fuchs, advancing therapies that target endothelial cell health, while others in dry eye are rethinking how we measure outcomes to better reflect what patients actually feel day to day. These efforts are not happening in isolation; they’re part of a broader movement toward collaboration, shared learning, and collective problem-solving. Because if the front of the eye has taught us anything, it’s that clarity rarely comes from going it alone.
So yes, anterior segment trials come with their fair share of challenges, but that reality is exactly what sparks creativity, fuels collaboration, and ultimately leads to better solutions.
Eye think … that’s the best kind of “trouble” to be in.